NASDAQ:PROK ProKidney (PROK) Stock Price, News & Analysis $1.83 +0.02 (+1.10%) Closing price 05/29/2026 04:00 PM EasternExtended Trading$1.81 -0.02 (-1.04%) As of 05/29/2026 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About ProKidney Stock (NASDAQ:PROK) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get ProKidney alerts:Sign Up Key Stats Today's Range$1.74▼$1.8650-Day Range$1.55▼$2.1852-Week Range$0.54▼$7.13Volume1.00 million shsAverage Volume816,442 shsMarket Capitalization$552.77 millionP/E RatioN/ADividend YieldN/APrice Target$7.40Consensus RatingModerate Buy Company Overview ProKidney, Inc. (NASDAQ: PROK) is a clinical-stage biotechnology company focused on developing cell-based therapies for kidney diseases. The company’s research and development activities center on harnessing human-derived proximal tubule cells to address conditions such as acute kidney injury (AKI) and chronic kidney disease (CKD). By targeting the underlying cellular mechanisms of renal injury and dysfunction, ProKidney aims to offer novel regenerative medicine approaches that go beyond current supportive care options. ProKidney’s lead programs utilize proprietary methods for isolating and expanding renal epithelial cells to create injectable therapeutic products. These candidates are designed to mitigate inflammatory responses, promote tissue repair and reduce the progression of kidney damage in hospitalized patients at risk of AKI, including those undergoing major surgery or experiencing sepsis. In addition to its clinical-stage portfolio, the company maintains preclinical efforts exploring broader applications in CKD and related nephrology indications. Founded in 2015 and headquartered in Massachusetts, ProKidney completed its initial public offering in 2022, trading on the NASDAQ under the ticker PROK. The management team comprises professionals with expertise in nephrology research, cell therapy manufacturing and clinical development. ProKidney conducts its clinical trials predominantly in the United States, collaborating with academic medical centers and specialized contract research organizations to advance its pipeline toward regulatory milestones. AI Generated. May Contain Errors. Read More ProKidney Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks38th Percentile Overall ScorePROK MarketRank™: ProKidney scored higher than 38% of companies evaluated by MarketBeat, and ranked 701st out of 870 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.9 / 5Analyst RatingModerate Buy Consensus RatingProKidney has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 1 strong buy rating, 4 buy ratings, 1 hold rating, and 2 sell ratings.Upside PotentialProKidney has a consensus price target of $7.40, representing about 304.4% upside from its current price of $1.83.Amount of Analyst CoverageProKidney has only been the subject of 3 research reports in the past 90 days.Read more about ProKidney's stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for ProKidney are expected to decrease in the coming year, from ($0.49) to ($0.68) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of ProKidney is -3.45, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of ProKidney is -3.45, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Read more about ProKidney's valuation and earnings. Short Interest0.0 / 5Short Interest LevelBearish Percentage of Shares Shorted10.59% of the float of ProKidney has been sold short.Short Interest Ratio / Days to CoverProKidney has a short interest ratio ("days to cover") of 25.22, which indicates bearish sentiment.Change versus previous monthShort interest in ProKidney has recently increased by 5.36%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldProKidney does not currently pay a dividend.Dividend GrowthProKidney does not have a long track record of dividend growth. News and Social Media2.5 / 5News Sentiment0.93 News SentimentProKidney has a news sentiment score of 0.93. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.83 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for ProKidney this week, compared to 3 articles on an average week.MarketBeat FollowsOnly 1 people have added ProKidney to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Company Ownership1.3 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, ProKidney insiders have not sold or bought any company stock.Percentage Held by Insiders39.83% of the stock of ProKidney is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions51.59% of the stock of ProKidney is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about ProKidney's insider trading history. Receive PROK Stock News and Ratings via Email Sign-up to receive the latest news and ratings for ProKidney and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. PROK Stock News HeadlinesProKidney shareholders reaffirm board and auditor at 2026 meetingMay 29 at 5:30 PM | tipranks.comFY2030 EPS Estimates for ProKidney Lowered by HC WainwrightMay 20, 2026 | americanbankingnews.comOne page of the SpaceX S-1 will move this stock overnightWhen SpaceX files its S-1 in June, the SEC will require full disclosure of operating expenses - including power consumption for 1 million GPUs, a cost that rivals entire cities. That disclosure will name the supplier. One small, publicly traded power infrastructure company sits at the center of this - carrying a $1.5 billion backlog and priced like a utility. Dylan Jovine has the full breakdown.May 30 at 1:00 AM | Behind the Markets (Ad)ProKidney (NASDAQ:PROK) Receives "Buy" Rating from HC WainwrightMay 19, 2026 | americanbankingnews.comProKidney Corp. Reports Phase 3 PROACT 1 Study Enrollment Progress and Q1 2026 Financial ResultsMay 15, 2026 | quiverquant.comQProKidney Reports First Quarter 2026 Financial Results and Business HighlightsMay 15, 2026 | globenewswire.comProKidney (PROK) Appoints Greg Madison as CCO to Lead Commercial Strategy for RilparencelMay 2, 2026 | finance.yahoo.comProKidney Corp. Class AApril 14, 2026 | edition.cnn.comSee More Headlines PROK Stock Analysis - Frequently Asked Questions How have PROK shares performed this year? ProKidney's stock was trading at $2.24 at the start of the year. Since then, PROK stock has decreased by 18.3% and is now trading at $1.83. How were ProKidney's earnings last quarter? ProKidney Corp. (NASDAQ:PROK) released its quarterly earnings results on Friday, May, 15th. The company reported ($0.14) EPS for the quarter, missing analysts' consensus estimates of ($0.13) by $0.01. The firm had revenue of $0.23 million for the quarter, compared to analyst estimates of $0.10 million. Who are ProKidney's major shareholders? Top institutional investors of ProKidney include Renaissance Technologies LLC (0.41%), Bank of America Corp DE (0.25%), Amundi (0.10%) and OMERS ADMINISTRATION Corp (0.02%). Insiders that own company stock include Control Empresarial De Capital, Pablo G Legorreta, Darin J Weber and Brian Jg Pereira. View institutional ownership trends. How do I buy shares of ProKidney? Shares of PROK stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of ProKidney own? Based on aggregate information from My MarketBeat watchlists, some other companies that ProKidney investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Broadcom (AVGO), Netflix (NFLX), Palo Alto Networks (PANW) and Tesla (TSLA). Company Calendar Last Earnings5/15/2026Today5/30/2026Next Earnings (Estimated)8/11/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Yellow Zone (2m+) 1-Year History May 25 Aug 25 Nov 25 Feb 26 May 26 PROK's financial health is in the Yellow zone, according to TradeSmith. PROK has been in this zone for over 2 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - DRUGS Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:PROK CIK1850270 Webwww.prokidney.com Phone336-999-7028FaxN/AEmployees3Year FoundedN/APrice Target and Rating Average Price Target for ProKidney$7.40 High Price Target$12.00 Low Price Target$1.00 Potential Upside/Downside+304.4%Consensus RatingModerate Buy Rating Score (0-4)2.50 Research Coverage8 Analysts Profitability EPS (Trailing Twelve Months)($0.53) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$68.99 million Net Margins-8,131.50% Pretax Margin-17,599.32% Return on EquityN/A Return on Assets-21.39% Debt Debt-to-Equity RatioN/A Current Ratio9.06 Quick Ratio9.06 Sales & Book Value Annual Sales$890 thousand Price / Sales621.09 Cash FlowN/A Price / Cash FlowN/A Book Value($3.39) per share Price / Book-0.54Miscellaneous Outstanding Shares302,060,000Free Float181,750,000Market Cap$552.77 million OptionableOptionable Beta1.70 Social Links 10 Stocks Powering The Next AI Boom The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation. Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.Get This Free Report This page (NASDAQ:PROK) was last updated on 5/30/2026 by MarketBeat.com Staff. From Our PartnersCODE RED: AI Meltdown Imminent?After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to tri...Paradigm Press | SponsoredTrump's gold order: the announcement they won't put on the front pageOn August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredTrump just signed itA recent policy development is drawing attention from income-focused investors. According to one analyst, c...Investors Alley | SponsoredYour book attachedYour Download Link (Expiring) If you still haven't downloaded the free Simple Options Trading For Beginners...Profits Run | SponsoredPH: Do THESE 4 things to your bank account now …In a few short months, the US government could gain unprecedented powers over personal bank accounts - includi...Weiss Ratings | SponsoredI paid $5,000 to hear Elon say thisOne investor paid $5,000 to be in a private room with Elon Musk in Los Angeles - and what he heard confirmed a...InvestorPlace | SponsoredSkip the Line Opportunity: The SpaceX IPOFormer tech executive and angel investor Jeff Brown - who identified Bitcoin, Tesla, and Nvidia before their h...Brownstone Research | SponsoredHey, it's Jon Najarian. The SpaceX IPO is right around the corner. But I discovered Elon may have something BIGGER planned. Check this out before June 9th...After being invited to the SpaceX launch headquarters in Cape Canaveral from one of Elon's top lobbyists… Hall...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ProKidney Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Share ProKidney With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
